DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) influences corticotropin release, somatostatin inhibition, stress adaptation, blood pressure normalization, and nociception. Emerging studies explore its roles in depression, metabolic resilience, and mitigation of free-radical damage.

DSIP stands for Delta Sleep-Inducing Peptide, described for promoting and stabilizing natural sleep patterns. Beyond sleep, DSIP is also described as helping manage stress levels, normalizing blood pressure, influencing pain perception, and affecting hormone activity during sleep.

Deeper Research Notes (Summary):
• DSIP is described as interacting with the neurotransmitter GABA, which is associated with falling asleep and staying asleep—often discussed in the context of mental health and recovery.
• It is described as increasing endocrine-related activity during sleep (with mentions of increased release of growth hormone and thyroid hormone).
• DSIP is also described as acting on opioid receptors in the brain—discussed in the context of pain perception and easing withdrawal symptoms related to opioid substances.

Dosing & Timing (As Listed):
Intent: The goal is described as restoring normal sleep patterns; dosing is noted to continue based on response.

Caution & Contraindications:
Caution: May cause headache, fatigue, stomach discomfort, and may disrupt sleep.
Contraindications: Individuals with an active or history of cancer or hormonal imbalances.

Reconstitution Options (Vial Formats):
• 2 mg
• 5 mg

Reconstitution (General Handling):
• Use sterile technique and follow your product label/spec sheet for diluent type and volume.
• Add diluent slowly along the vial wall to minimize foaming.
• Gently swirl/roll until fully dissolved (avoid vigorous shaking).
• Store according to label guidance and protect from light as applicable.

Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

Molecular Formula: C35H48N10O15

Molecular Weight: 848.82 g/mol

CAS Number: 62568-57-4

Synonyms: Emideltide, DSIP nonapeptide, Deltaran

DSIP was discovered during slow-wave sleep and can normalize sleep cycles in animal and human studies, though results vary. Reports include promotion of slow-wave sleep, paradoxical sleep suppression, transient arousal before sedation, and subjective improvements in sleep quality and latency among chronic insomnia cohorts.

Discrepancies between subjective outcomes and EEG metrics suggest DSIP may modulate natural (non-pharmacologic) sedation pathways, prompting researchers to revisit evaluation methods for sleep quality.

DSIP reduced chronic pain perception and improved mood in preliminary clinical settings, potentially via central opioid receptors—without apparent dependency. It mitigated withdrawal symptoms in alcohol and opiate detox studies, with 87–97% of patients reporting dramatic relief.

Animal models demonstrate DSIP’s ability to maintain oxidative phosphorylation under hypoxia, limiting metabolic injury in stroke and myocardial ischemia scenarios while curbing free-radical formation.

DSIP levels are reduced in individuals with major depressive disorder, aligning with findings linking sleep regulation, MAO-A modulation, and hypothalamic-pituitary-adrenal axis changes. Animal data support DSIP’s antioxidant contribution to neuroprotection.

Long-term administration in mice yielded a 2.6-fold reduction in spontaneous tumors and fewer chromosomal abnormalities. Additional studies indicate protection against chemotherapy-induced CNS dysfunction and enhanced survival following cerebral ischemia.

DSIP is detected in peripheral tissues at levels comparable to CNS concentrations, hinting at systemic regulatory roles. It may act as a hypothalamic hormone influencing cardiovascular tone, thermogenesis, lymphokine networks, and skeletal muscle growth via somatostatin inhibition.